跳至主要内容
临床试验/NCT06474819
NCT06474819招募中不适用

Left Septal or Deep Septal Pacing to Prevent Pacing-induced Cardiomyopathy

Institut d'Investigació Biomèdica de Bellvitge8 个研究点 分布在 1 个国家目标入组 326 人开始时间: 2024年7月12日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
326
试验地点
8
主要终点
Pacing-induced cardiomyopathy

研究概览

简要总结

Multicenter randomized controlled trial which will include patients with left ventricular ejection fraction >50% requiring a first implant of a cardiac pacemaker with expected high pacing percentages.

Patients will be randomized 1:1 to right ventricular apical pacing vs left septal or deep septal pacing. The primary endpoint will be pacing-induced cardiomyopathy during the first year of follow-up.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • First implant of a single-chamber or dual chamber pacemaker due to persistent bradycardia associated with high degree atrio-ventricular (AV) block (complete AV block or second degree type II AV block), with second-degree type I AV block (symptomatic or associated with intra-hisian or infra-hisian block), or with atrial fibrillation with symptomatic slow ventricular rate (<45lpm).
  • LVEF>50% at echocardiography performed maximum 7 days before pacemaker implant.
  • Informed consent signature.

排除标准

  • Life expectancy <12 months
  • Severe cardiac valvular abnormality requiring intervention
  • Unstable Angina, Acute myocardial infarction, coronary revascularization, valvular surgery or valvular percutaneous intervention in the 90 days prior to pacemaker implant.
  • Inclusion in another trial which may influence the results of this study.

结局指标

主要结局

Pacing-induced cardiomyopathy

时间窗: 12 months

Decrease in the left ventricular ejection fraction (LVEF) by \>10% as compared to the LVEF before pacemaker implant and final LVEF\<45%.

次要结局

  • heart failure(12 months)
  • LVEF during follow-up(12 months)
  • Mitral and tricuspid regurgitation(12 months)
  • Brain Natriuretic Peptide levels(12 months)
  • New York Heart Association (NYHA) class(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Andrea Di Marco

Principal Investigator

Institut d'Investigació Biomèdica de Bellvitge

研究点 (8)

Loading locations...

相似试验